Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease

Overview

Journal J Pediatric Infect Dis Soc

Publisher Oxford University Press

Specialties Infectious Diseases
Pediatrics

Date 2019 Jun 12

PMID 31183500

Citations 3

Authors

Maria Perez Marin

Laurent Arthur Decosterd

Pascal Andre

Thierry Buclin

Thomas Mercier

Kristina Murray

Mattia Rizzi

Pascal Meylan

Katia Jaton-Ogay

Onya Opota

Carole Gengler

Marie-Helene Perez

Julia Natterer

Sandra Andrea Asner

Affiliations

Soon will be listed here.

Abstract

Little information on the efficacy and pharmacokinetics of letermovir among immunocompromised children is currently available. We describe here the use of letermovir in a 2-year-old immunocompromised child with ganciclovir-resistant cytomegalovirus disease who required extracorporeal membrane oxygenation. Detailed information on therapeutic-drug-monitoring measures and dosage adjustments for letermovir is provided.

Citing Articles

Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients.

Korholz K, Fuller M, Hennies M, Holterhus M, Hagedorn S, Ahlmann M Paediatr Drugs. 2022; 25(2):225-232.

PMID: 36572834 PMC: 9931806. DOI: 10.1007/s40272-022-00547-6.

Challenges, Recent Advances and Perspectives in the Treatment of Human Cytomegalovirus Infections.

Chen S, Wang S, Chen Y Trop Med Infect Dis. 2022; 7(12).

PMID: 36548694 PMC: 9784992. DOI: 10.3390/tropicalmed7120439.

Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review.

Hiskey L, Madigan T, Ristagno E, Razonable R, Ferdjallah A Front Pediatr. 2022; 10:1039938.

PMID: 36507142 PMC: 9727199. DOI: 10.3389/fped.2022.1039938.